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Abstract: Background: To evaluate whether a model based on radiomic and clinical features may 
be associated with lymph node (LN) status and overall survival (OS) in lung cancer (LC) patients; 
to evaluate whether CT reconstruction algorithms may influence the model performance. Methods: 
patients operated on for LC with a pathological stage up to T3N1 were retrospectively selected and 
divided into training and validation sets. For the prediction of positive LNs and OS, the Least 
Absolute Shrinkage and Selection Operator (LASSO) logistic regression model was used; 
univariable and multivariable logistic regression analysis assessed the association of clinical-
radiomic variables and endpoints. All tests were repeated after dividing the groups according to the 
CT reconstruction algorithm. p-values < 0.05 were considered significant. Results: 270 patients were 
included and divided into training (n = 180) and validation sets (n = 90). Transfissural extension was 
significantly associated with positive LNs. For OS prediction, high- and low-risk groups were 
different according to the radiomics score, also after dividing the two groups according to 
reconstruction algorithms. Conclusions: a combined clinical–radiomics model was not superior to a 
single clinical or single radiomics model to predict positive LNs. A radiomics model was able to 
separate high-risk and low-risk patients for OS; CTs reconstructed with Iterative Reconstructions 
(IR) algorithm showed the best model performance. 
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1. Introduction 
The lung represents the second most frequent site of cancer each year, and the first cause of 
death from cancer [1]. For early stages, when surgery is the primary option, complete lymph node 
(LN) excision with a microscopic evaluation is the most accurate method for determining LN 
metastasis. However, the best local control and decreased risk of residual lesions guaranteed by the 
dissection of a high number of LNs is associated with greater trauma for patients, such as prolonged 
air leaks, excessive chest tube drainage and prolonged hospitalization [2–4]. A method that could 
non-invasively predict the presence of LN metastasis would therefore be helpful to guide systematic 
dissection and might be considered, for example, in patients with small tumours and no apparent 
enlarged LNs [5], or in the presence of many co-morbidities. 
Radiomics is an emerging translational field of research, aiming to extract mineable high-
dimensional data from clinical images, containing information that may reflect the underlying patho-
physiology of a tissue [6]. Many recent studies have evaluated the associations between radiomics 
and the prognosis of various tumours, such as lung adenocarcinoma [7–9], renal cancer [10], 
hepatocellular carcinoma [11,12], glioblastoma [13], and ovarian cancer [14]. 
Some methodological issues have been raised regarding radiomics studies, including the 
possibility that differences in quantitative data may depend on different parameters of acquisition 
and reconstruction [15]. It has also been widely demonstrated that at least internal, possibly external, 
and independent validation of the model is always needed [16]. 
The purpose of this study was to evaluate whether a model based on quantitative CT radiomic 
and clinical features of lung cancer patients may be associated with LN status and with overall 
survival (OS); a secondary purpose was to assess the influence of CT reconstruction algorithms on 
the quantitative parameters and on the performance of the predictive models. 
2. Results 
2.1. Patients 
All patients underwent anatomical resection with radical lymphadenectomy; no cases of 
intraoperative nodal upstaging to pN2 from cN0 or cN1 were observed. 
A total of 270 patients were enrolled and randomly divided into training (n = 180) and validation 
datasets (n = 90). The histological type was adenocarcinoma or squamous cell carcinoma in 254/270 
patients; other types were present in 16/270 patients. The distribution of histological type between 
the training set and the validation set did not show significant differences (p = 0.16). Other baseline 
characteristics of the cohort are summarized in Table 1. 
Table 1. Baseline characteristics of the study population. 
Characteristic All Patients (N = 270) 
N (%) 
Training Set 
(N = 180) 
N (%) 
Validation Set 
(N = 90) 
N (%) 
Age (years) ^ 67.4 (61.0–72.6) 66.6 (60.7–72.2) 68.4 (62.3–72.8) 
Gender    
Female 103 (38%) 74 (41%) 29 (32%) 
Male 167 (62%) 106 (59%) 61 (68%) 
Grading    
1 30 (13%) 21 (14%) 9 (12%) 
2 82 (36%) 56 (37%) 26 (33%) 
3 117 (51%) 74 (49%) 43 (55%) 
Cancers 2020, 12, 1432 3 of 16 
 
Missing 41 29 12 
Side    
Right 153 (57%) 102 (57%) 51 (57%) 
Left 117 (43%) 78 (43%) 39 (43%) 
Site    
Upper 154 (57%) 101 (56%) 53 (59%) 
Medium 12 (4%) 9 (5%) 3 (3%) 
Lower 93 (34%) 65 (36%) 28 (31%) 
Mixed 11 (4%) 5 (3%) 6 (7%) 
Nodule size (mm) ^ 31 (18–45) 28 (17–45) 36 (22–46) 
pT    
0 3 (1%) 1 (1%) 2 (2%) 
1 97 (36%) 74 (41%) 23 (26%) 
2 124 (46%) 76 (42%) 48 (53%) 
3 46 (17%) 29 (16%) 17 (19%) 
pN    
pN0 199 (74%) 139 (77%) 60 (67%) 
pN1 71 (26%) 41 (23%) 30 (33%) 
Algorithm type    
FBP 187 (69%) 130 (72%) 57 (63%) 
IR 83 (31%) 50 (28%) 33 (37%) 
Status    
Alive 202 (75%) 140 (78%) 62 (69%) 
Deceased 68 (25%) 40 (22%) 28 (31%) 
Follow-up (months) ^ 46.1 (29.8–63.3) 47.0 (32.0–65.2) 45.5 (22.7–59.6) 
FBP = Filtered Back Projection; IR = Iterative Reconstructions; ^ Median (InterQuantile Range). 
The clinical and radiological parameters are comparable between the two datasets, although a 
slightly higher percentage of patients with pT > 1 was randomly allocated in the validation set 
(standardized mean difference = 0.21). 
A total of 881 radiomic features was calculated for each patient. The numbers of radiomic 
features which survived after elimination of identical features and selected as the most stable and 
reproducible after phantom analysis and Analysis of Variance (ANOVA) are reported in Figure S1 
for the different cases (analysis performed on the entire Filtered Back Projection (FBP) + Iterative 
Reconstructions (IR) dataset and analysis performed separating the patients according to FBP or IR 
reconstructing algorithm). 
2.1.1. Lymph Nodes 
Analysis on the Entire Dataset (FBP + IR) 
The radiomics score obtained for the prediction of positive lymph nodes (LNs) on the entire 
training dataset consisted of three radiomic features: ClusterShade from GLCM25 category calculated 
along 135° direction with four voxels offset (GLCM25135, 4_CIusterShade), 70th percentile of the 
intensity values in the cumulative histogram (IH_70PercentileArea), and the maximum diameter 
evaluated on the 3D lesion volume (Shape_Max3DDiameter). Coefficients of the Least Absolute 
Shrinkage and Selection Operator (LASSO) logistic regression model for the calculation of the 
radiomics score are shown in Figure 1. 
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Figure 1. Values of the coefficients of the Least Absolute Shrinkage and Selection Operator (LASSO) 
logistic regression model for the prediction of positive lymph nodes according to radiomic features 
(training set). The plot shows the model coefficients of the three radiomic features selected as 
significantly associated with lymph node status. These coefficients were used to calculate the 
radiomics score used to predict lymph node status in the validation set. 
Among clinical variables, univariable analysis in the training set showed that mixed site 
(meaning that the tumour showed a transfissural growth into two lobes) and nodule size (the larger, 
the worse) were significantly associated with positive LNs. Multivariable analysis confirmed the 
importance of the site (Table 2). 
Table 2. Univariable and multivariable Odds Ratios for the association between clinical variables with 
positive lymph nodes (training set). 
Variable 
Univariable Analysis Multivariable Analysis * 
OR (95%CI) p-value OR (95%CI) p-value 
Age (years) 1.02 (0.98–1.06) 0.38 - - 
Gender (females vs males) 0.78 (0.38–1.61) 0.50 - - 
Side (left vs right) 0.61 (0.29–1.26) 0.18 - - 
Site     
Medium vs. Upper 0.42 (0.05–3.67) 0.14 0.35 (0.04–3.20) 0.13 
Lower vs. Upper 0.85 (0.39–1.82) 0.22 0.79 (0.36–1.72) 0.27 
Mixed vs. Upper 13.57 (1.44–127.43) 0.01 10.94 (1.13–105.40) 0.02 
Nodule size (mm) 1.01 (1.00–1.02) 0.07 1.01 (1.00–1.02) 0.12 
CI = Confidence Intervals; OR = Odds Ratio; * includes radiomic score and clinical variables 
significantly associated with lymph nodal status at univariable analysis (p < 0.10). Significant values 
in bold. 
Receiving Operating Characteristic (ROC) curves for prediction of positive LNs showed no 
significant differences in performance of the combined clinical–radiomics model, as compared to a 
single radiomics or single clinical model in the training and validation sets (Figure 2). 
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(a) (b) 
Figure 2. ROC curves for prediction of positive lymph nodes in (a) the training set and (b) the 
validation set according to clinical, radiomics and clinical–radiomics models. The plots show the ROC 
curves of the three models and the associated values of the Area under the Curves (AUC). 
Analysis on Datasets Separated According to FBP or IR Algorithm 
Figure 3 shows coefficients of the LASSO logistic regression model for the radiomics score 
prediction of positive LNs, separately for FBP and IR (training set). 
 
(a) 
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Figure 3. Values of the coefficients of the LASSO logistic regression model for the prediction of 
positive lymph nodes according to radiomic features for (a) FBP algorithm and (b) IR algorithm 
(training set). The plots show the model coefficients of the (a) five and (b) eight radiomic features 
selected as significantly associated with lymph nodes in the two subsets of patients with (a) FBP 
algorithm and (b) IR algorithm. These coefficients were used to calculate the corresponding radiomic 
scores used to predict lymph node status in the validation set for the two separate sub-samples. 
In both cases, a prevalent role of the textural features is evident, whereas this was not observed 
when considering the entire dataset including both FBP and IR. ROC curves in the training and 
validation sets acquired with FBP and IR were separately evaluated (Figure S2). 
The overall performance of the combined model to predict LN positivity was higher for IR than 
FBP algorithms, with an Area Under the Curve (AUC) of 0.76 for IR compared to 0.61 for FBP in the 
validation set. 
2.1.2. Overall Survival 
Radiomic Analysis on the Entire Dataset (FBP + IR) 
Looking at OS prediction, in the entire training set (including both FBP and IR), the Cox 
regression LASSO model selected six radiomic features for the radiomics score (Figure 4). 
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Figure 4. Values of the coefficients for Cox regression LASSO model for prediction of overall survival 
according to radiomic features (training set). The plot shows the model coefficients of the six radiomic 
features selected as significantly associated with overall survival. These coefficients were used to 
calculate the radiomic score used to predict overall survival in the validation set. 
Table 3 shows parameters associated with OS in high-risk and low-risk patients, defined 
according to the third quartile of the radiomics score. 
Table 3. Overall Survival in high-risk and low-risk patients according to the radiomics score. 
 Training Data Set Validation Data Set 
 High-Risk 
Group * 
Low-Risk 
Group 
Total High-Risk 
Group * 
Low-Risk 
Group 
Total 
No. of 
patients 45 (25%) 135 (75%) 180 (100%) 20 (22%) 70 (78%) 90 (100%) 
Follow-up 
time 
      
Median 
(IQR) 
37.0 (19.3-62.2) 
49.0 (35.5–
68.4) 
47.0 (32.6–
66.1) 
33.0 (17.2–
56.4) 
47.0 (28.9–
61.6) 
46.0 (23.6-
60.6) 
Shortest 
(months) 
0.8 0.9 0.8 1.6 0.2 0.2 
No. of 
events 
      
At 1 year 8 (18%) 3 (2%) 11 (6%) 3 (15%) 3 (4%) 6 (7%) 
At 3 years 17 (38%) 14 (10%) 31 (17%) 7 (35%) 13 (19%) 20 (22%) 
At 5 years 20 (44%) 19 (13%) 39 (22%) 9 (45%) 16 (23%) 25 (29%) 
* Radiomics score higher than the third quartile. 
The percentage of deaths at the second and third years in the validation set for high-risk patients 
was almost double that of the low-risk patients (respectively, 35% vs. 19% and 45% vs. 23%). As 
shown in Figure 5, a significant difference in OS for the high- and low-risk groups according to the 
radiomics score was observed in the training set and confirmed in the validation set. 
 
Figure 5. Kaplan–Meier curves and Log–Rank test for high-* and low-risk groups according to the 
radiomics score (* Radiomics score higher than the third quartile (q3)). 
Radiomic Analysis on Datasets Separated According to FBP or IR Algorithm 
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The above-described results were further confirmed after dividing the two groups according to 
the reconstruction algorithms (Figure 6). 
 
(a) 
 
(b) 
Figure 6. Kaplan–Meier curves and Log–Rank test for high * and low-risk groups according to the 
radiomics score for (a) FBP algorithm and (b) IR algorithm (* Radiomics score higher than the third 
quartile (q3)). 
Radiomic and Clinical Analysis 
Clinical variables associated with OS in the model including both FBP and IR algorithms were 
tumour side, site and pT—tumour site and pT were associated with OS for the subgroup of patients 
with FBP algorithm, while only tumour site was associated with OS for the subgroup of patients with 
IR algorithm. 
Table 4 summarizes the performance of the models including radiomic only, clinical only, and 
clinical–radiomic parameters, on both the entire FBP+IR datasets and on datasets separated according 
to reconstruction algorithm. 
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The best model performance for prediction of OS was obtained with the combined clinical–
radiomic model for CT reconstructed with the IR algorithm. 
Table 4. Model performance statistics. 
Model Algorithm C-Index (95%CI) Training Set C-Index (95%CI) Validation Set 
Radiomic FBP + IR 0.73 (0.66–0.80) 0.59 (0.47–0.70) 
Clinical (side, site, pT) FBP + IR 0.78 (0.71–0.85) 0.53 (0.41–0.65) 
Clinical–radiomic  FBP + IR 0.77 (0.69–0.84) 0.57 (0.46–0.69) 
Radiomic FBP 0.69 (0.61–0.77) 0.61 (0.46–0.76) 
Clinical (site, pT) FBP 0.66 (0.57–0.75) 0.57 (0.43–0.72) 
Clinical–radiomic FBP 0.70 (0.63–0.78) 0.61 (0.46–0.75) 
Radiomic IR 0.82 (0.66–0.98) 0.82 (0.53–1.00) 
Clinical (site) IR 0.67 (0.50–0.85) 0.65 (0.38–0.91) 
Clinical–radiomic IR 0.84 (0.68–1.00) 0.89 (0.60–1.00) 
3. Discussion 
In this series, selected clinical and radiomic features showed association with the positivity of 
LN, although the combined radiomics–clinical model did not perform better than a single clinical or 
radiomics model. Among the clinical features, the mixed site was significant in the univariate and 
multivariate analysis. The importance of this feature is recognized by its role in Tumor-Nodes-
Metastasis (TNM) staging, where the invasion of the visceral pleura makes the tumour belong to the 
T2 category, despite its size [17]. This result is concordant also with Li et al., who demonstrated a 
significant association between adjacent lobe invasion through pleural fissure and LN positivity [18]. 
The size of the tumour, measured on an axial image, was borderline-significant in the univariable 
and multivariable analysis. Size is a well-known feature for prognosis, as demonstrated by the sub-
division of tumours in the T category according to size [17]. Its importance is confirmed in our series 
by the better performance of the single clinical model, after the inclusion of size as a feature. Likewise, 
the importance of size as a prognostic factor for LN positivity is demonstrated by one radiomic 
feature included in the score, the Shape_Max3DDiameter. This feature represents a measure of the 
maximum dimension of the lesion, evaluated in 3D, not directly related to the volume and is more 
precise than the maximum axial diameter. This may also account for the slightly better performance 
of the radiomics model compared to the clinical model, where the Max3DDiameter radiomic feature 
may provide a more precise definition of size than the maximum axial diameter. Other significant 
features in the radiomics score for LN positivity prediction were IH_70PercentileArea and 
GLCM25135, 4_ClusterShadeClShade. IH_70PercentileArea belongs to the Intensity Histogram 
category and roughly indicates that the mean Hounsfield Units (HU) number within the lesion is 
associated with LN status. GLCM25135, 4_ClusterShade, belonging to the GLCM category, is a measure 
of the global skewness. When the Cluster Shade parameter is high, the distribution of HU values is 
asymmetric. In our series, low values of this feature, that may be associated with intratumoral 
necrosis, were more frequently associated with positive LNs, whereas high values, encountered in 
lesions with calcifications and ground-glass opacities, were associated with negative LNs. 
Despite the abovementioned associations, the combined clinical and radiomics model did not 
perform better than a single clinical or radiomics model. This result is discordant with Tan et al., who 
demonstrated that, in patients with resectable oesophageal carcinoma, a radiomics nomogram 
provided a good risk estimation of LN metastasis and outperformed size criteria [19]. However, 
unlike these authors, we did not evaluate LN radiomic features, because our purpose was to predict 
the presence of positive LNs according to the characteristics of the primary tumour. Conversely, Yang 
et al. [20] demonstrated a good performance of a radiomics-based nomogram extracted from lung 
tumour to predict LN metastases. Although we used a similar method, by performing the radiomics 
analysis on the lung tumour volume, our results may be different because Yang et al. included 
patients with CT examinations acquired with the same parameters and reconstructed with the same 
algorithm [20]. In this regard, our entire sample is less homogeneous, because we included CTs 
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obtained from different scanners and reconstructed with two different algorithms. However, it must 
be pointed out that from a methodological point of view, we tried to take this into account by 
performing a preliminary selection with ANOVA to choose features that were not significantly 
affected by the use of different scanners or reconstruction algorithms. This is important because 
reproducibility and differences in acquisitions and reconstructions are frequent issues in 
retrospective studies, which currently represent the majority of radiomics studies. 
As a consequence, the poor performance of our predictive model, including radiomic and 
clinical parameters, as compared to the model based on clinical variables alone, could be due to the 
fact that feature selection with ANOVA may have eliminated features which potentially carry 
relevant predictive information, but are significantly affected by the scanner or reconstruction 
algorithm. It is possible that, in a more homogeneous dataset, such features would survive the feature 
selection process and would enter the predictive model with a significant improvement in terms of 
performance. 
In order to verify this hypothesis, we performed a separate analysis, according to reconstruction 
algorithms: FBP, the most common analytical reconstruction method, which uses a 1D filter on the 
projection data before back-projecting them onto the image space [20,21], and IR, which optimizes 
the reconstruction with multiple iterations of forward and back projection between image and 
projection space. With the advances in computing technology, IR has progressively replaced FBP in 
routine CT practice because it makes it possible to reduce artefacts [22]. Therefore, while retrospective 
databases are likely to include CT images reconstructed with either FBP or IR, future studies will 
mainly involve IR, unless FBP is proved to be more indicated for quantitative analysis and expressly 
added to the clinical IR reconstruction. In this series, for association with LN status, the radiomics 
score associated with FBP included five quantitative features, where the most important coefficients 
were attributed to two different features of Correlation type, belonging to the GLCM25 category. 
Correlation features measure the linear dependency of voxel intensities at each point with those of 
neighbouring pixels at fixed distances along different directions. In our series, this feature was high 
for lung tumours with air bronchograms and with high heterogeneity due to contrast-enhancement 
(particularly in the presence of subtle vascularization within the tumour). For CT examinations 
reconstructed with IR, the most important coefficients were attributed to the InverseVariance feature 
from the GLCM2.5 category, calculated along 180° direction with one voxel offset, and to the 
LocalEntropyMax feature from ID category. The larger the changes in grey values, the higher the 
GLCM contrast; the lower the values, corresponding to an inhomogeneous texture, the higher the 
association with LN positivity. LocalEntropyMax (Maximum of Local Entropy) is a primary-order 
statistics feature measuring the entropy within the Region of Interest (ROI), and shows high values 
even for small areas of entropy within a single voxel. Higher local entropies were associated with LN 
positivity. These results confirmed that focusing on a more homogeneous dataset (as far as CT 
reconstruction algorithm is concerned) may make it possible to identify texture features significantly 
associated with LN status, not revealed in a heterogeneous dataset. We were still not able to 
demonstrate that, in a homogeneous dataset, the performance of a combined clinical–radiomics 
model is superior to a model based on clinical or radiomic data only, probably due to the fact that 
dividing the dataset according to a CT reconstruction algorithm considerably reduced the size of each 
training and validation set. Nonetheless, promising results were found in the IR dataset (Figure S2), 
which may deserve to be further investigated on a larger sample. 
The analysis of association between clinical and radiomic features with OS showed a very good 
performance of the radiomics score, that significantly separated patients into high-risk and low-risk 
groups (p < 0.0001 in the training set; p = 0.012 in the validation set). Among radiomic features, 
GLCM25180, 1_InformationMeasureCorrelation1, GLRLM25_LongRunLowGrayLevel Emphasis, 
GOH_Kurtosis and Shape_Max 3DDiameter were included in the score. GLCM25180, 
1_InformationMeasureCorrelation1 belongs to the GLCM category and quantifies the degree of 
randomness within the tumour, in terms of entropy and statistical disorder. 
GLRLM25_LongRunLowGrayLevel Emphasis belongs to the GLRLM category, and quantifies runs, 
intended as consecutive pixels with the same grey level. GOH_Kurtosis indicates the flatness of the 
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curve of values, without concern for spatial relationships. A prevalent direction for the voxel intensity 
gradient indicates that structures within the 3D volume of interest (VOI) develop along a precise 
direction (e.g., an intratumoral vessel). Shape_Max 3DDiameter (see features of the radiomics score 
for LN) was associated with OS, with high values (large lesions) associated with worse OS. 
This study has some limitations. The number of patients with malignant lymph nodes (pN1) in 
our group was relatively small (71/270; 26%) and this may account for different results compared to 
previous papers. However, the inclusion of patients with pN2 introduced a bias related to the neo-
adjuvant chemotherapy. The CT examinations included in this study were performed over quite a 
long period of time (four years), and this may have affected the acquisition protocols. However, we 
specifically performed a preliminary ANOVA test to select stable and reproducible radiomic features. 
Furthermore, since the most important change in CT acquisition during the period selected was the 
reconstruction algorithm, we performed a separate analysis according to the algorithm used, as 
described. These subgroup analyses were performed on even smaller samples, which may have 
generated incidental results; they could therefore be considered as exploratory analyses that need to 
be validated in future, larger studies. Finally, segmentation was carried out by a single operator. 
Although this has been considered a limitation in previous studies [23], the inclusion of multiple 
slices to obtain a volume, instead of a single ROI, as well as the methods of extraction of the features 
by dedicated software may overcome this limitation. 
4. Materials and Methods 
Patient selection. The Institutional Review Board approved this retrospective study (UID 2172), 
waiving the need for informed consent. The study population was retrospectively selected from a 
database of patients with lung cancer staged up to T3 N1, operated on between 01/01/2012 and 
01/08/2016. Preoperative staging was performed by whole body CT and Fluorodeoxyglucose Positron 
Emission Tomography (FDG PET) scan; in the event of suspected cN2 disease, preoperative 
endobronchial ultrasound trans bronchial needle aspiration (EBUS TBNA) was performed to rule out 
or to confirm lymph node involvement. Inclusion criteria were: availability of pre-surgical CT at our 
Institution after contrast medium injection, with helical mode, 120 kVp, 2.5 mm slice thickness, 2.5 
mm spacing; reconstruction performed with “Body” filter and “Standard” convolution kernel; 
surgery performed at our Institution; availability of histology, pathological node status (pN0; pN1), 
grading. Exclusion criteria were: CT performed with parameters different to those specified above; 
pre-operative chemotherapy. 
CT imaging. Examinations were randomly performed on the following CT scanners: Lightspeed 
Ultra, Lightspeed 16; Optima 660; Discovery CT750 HD (all GE Healthcare, Milwaukee, WI, USA). 
All scans were acquired in the portal venous phase and segmentations were performed on that series. 
All scanners implemented current modulation; Light speed 16 and Light Speed Ultra were equipped 
only with longitudinal z-axis modulation, while Optima 660 and Discovery CT750 also had angular 
xy modulation. 
Clinical and radiological data recording. The following data were recorded: age; gender; 
grading; side; site (upper, medium, lower, mixed); axial nodule size; pT; pN; CT scanner; CT 
reconstruction algorithm (Filtered Back Projection, FBP, or Iterative Reconstruction, IR); exposure 
(mAs, defined as mA_central slice * RevolutionTime * 
SliceThickness)/(Pitch*TotalCollimationWidth); contrast medium (Visipaque® 320, GE Healthcare; 
Ultravist® 370, Bayer; Iomeron 350, Bracco Imaging; Xenetix 350, Guerbet); status (alive or deceased); 
date of last contact or death. 
Lesion segmentation: On each axial CT image including the lung nodule, a radiologist traced 
free-hand 2D regions of interest, resulting in a 3D volume of interest (VOI) that was converted into a 
DICOM RT Structure format (AW Server 2.0 workstation, GE Healthcare). 
Radiomic feature extraction: CT images and VOI were imported into the IBEX V 1.0 β tool 
(Imaging Biomarker Explorer Software [24]) for the extraction of radiomic features. The 
“Resample_VoxelSize” pre-processing was used to resample images to the same pixel size, chosen as 
the value most frequently observed in the dataset (0.7 × 0.7 mm2, the values in patient images ranging 
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from 0.59 × 0.59 mm2 to 0.98 × 0.98mm2). “Threshold_Image_MaskXF” pre-processing, that excludes 
voxels on the ROI edge having intensity outside a user-defined range, was used to exclude 
parenchyma voxels erroneously included during manual delineation (threshold: −400 Hounsfield 
Units). All the features available in IBEX for the following categories were extracted: Shape, Intensity 
Histogram (IH), Intensity Direct (ID), Grey Level Co-occurrence Matrix (GLCM) 2.5, Grey Level Run 
Length Matrix (GLRLM) 2.5, Neighbour Intensity Difference (NID) 2.5, and Gradient Orient 
Histogram (GOH). GLCM and GLRLM were calculated comparing voxel intensities along 8 different 
directions (0°, 45°, 90°, 135°, 180°, 225°, 270°, 315°) and with three different offsets between voxels (1, 
4 and 7 voxels). The full list of features calculated by IBEX for each category is reported in [24], also 
including references for feature definition and formula. The [0–4096] HU interval was discretized in 
256 bins for GLCM2.5 calculation, and 64 bins for the other categories. 
Statistical analysis 
Repeatability and reproducibility: In order to select the most stable and reproducible radiomic 
features, we first selected stable features with Overall Concordance Correlation Coefficient (OCCC) 
>0.95 based on the test-retest experiments on a phantom, where identical measures in different tests 
are expected. We then used one-way ANOVA to assess the features’ reproducibility according to 
contrast medium, scanner, reconstruction algorithm, and exposure. Features with significantly 
different means according to at least one of the abovementioned parameters were considered not 
robust and excluded. 
Training and validation datasets: We randomly selected 2/3 of the patients as a training dataset, 
and 1/3 as a validation dataset. 
Positive LN prediction: The Least Absolute Shrinkage and Selection Operator (LASSO) logistic 
regression model was used to select radiomic features associated with positive LNs. We combined 
selected features into a radiomics score. We assessed the predictive accuracy of the radiomics score 
for positive LNs by calculating the Area Under the Curve (AUC). The association of clinical variables 
(age, gender, side, site, and nodule size) with positive LNs was assessed with univariable and 
multivariable logistic regression analysis. A clinical score was obtained as a linear combination of the 
selected clinical variables weighted by their respective coefficients; the corresponding AUC was then 
calculated for both datasets. Finally, a radiomics–clinical score was obtained by applying a logistic 
regression multivariable model to the above-mentioned scores, and the corresponding AUC was 
calculated for both datasets. The AUC for the radiomics, clinical and clinical–radiomics models were 
compared with the DeLong test [25]. We replicated all the analyses separately on the two subgroups 
of patients with CT images reconstructed with FBP or IR algorithms. For each subgroup, AUCs for 
the radiomic, clinical and clinical–radiomics models were compared with the DeLong test [25]. 
OS prediction: Overall survival was calculated from the date of CT to the date of death or last 
follow-up, whichever occurred first. The LASSO Cox regression model was used to select the 
radiomic features predicting OS. We combined the selected features into a radiomics score as a linear 
combination of the selected features weighted by their respective coefficients. The association of the 
radiomics score with OS was assessed in the training and validation datasets by using Kaplan–Meier 
survival analysis. For this, the patients were classified into high-risk or low-risk groups according to 
the radiomics score, by using the third quartile as the threshold. The difference in the survival curves 
of the high-risk and low-risk groups was evaluated by using the Log–Rank test. The predictive 
accuracy of the radiomics score for OS was assessed in both datasets [26]. The association of clinical 
variables (age, gender, side, site, nodule size, histological type, grading, pT and pN) with OS was 
assessed with univariable and multivariable analysis. A clinical score was obtained as a linear 
combination of the clinical variables weighted by their respective coefficients. Finally, a combined 
radiomics–clinical score was obtained by applying a Cox regression multivariable model to the 
above-mentioned scores, and the corresponding C-index was calculated for the clinical–radiomics 
model in both datasets. 
To assess the role of reconstruction algorithms on the models, we replicated all the analyses 
separately on the two subgroups, according to FBP and IR algorithms. 
Cancers 2020, 12, 1432 13 of 16 
 
p-values < 0.05 were considered statistically significant. The analyses were performed using SAS 
software (SAS Institute Inc., Cary, USA), version 9.4 and R software (http://www.Rproject.org), 
version 3.5.3. (R Core Team, R Foundation for Statistical Computing, Vienna, Austria). More details 
are provided in the Supplementary Materials. 
Training and validation datasets: The subjects were randomly split into training and validation 
groups so that 2/3rd of subjects were included in the training group and 1/3rd in the validation group. 
This allocation proportion is commonly used to ensure the model is trained on a sufficient number 
of patients, in order to obtain precise parameter estimates. From a previously published paper, this 
commonly used strategy was demonstrated to be close to optimal for reasonably sized datasets (n ≥ 
100) with strong signals (i.e., 85% or greater full dataset accuracy) [27]. 
Positive LN prediction: The Least Absolute Shrinkage and Selection Operator (LASSO) logistic 
regression model was used to select radiomic features predicting positive LNs. First, a 10-fold cross-
validation was computed to find the best lambda parameter. The regularization strength was selected 
as the minimum value that maximized the Area Under the receiver operating characteristics Curve 
(AUC). The R package “glmnet” was used to perform the LASSO logistic regression on the training 
dataset with standardized features. The coefficients were then returned to the original scale. We then 
combined the selected features into a radiomics score as a linear combination of the selected features 
weighted by their respective coefficients. We also assessed the predictive accuracy of the radiomics 
score for positive LNs both in the training and in the validation datasets by calculating the AUC. The 
association of clinical variables (age, gender, side, site, and nodule size) with positive LNs was 
assessed with univariable and multivariable logistic regression analysis. Multivariable analysis 
included the clinical variables with a p-value < 0.10 at univariable analysis. A clinical score was 
obtained as a linear combination of the selected clinical variables weighted by their respective 
coefficients, and the corresponding AUC was calculated for the clinical model for both the training 
and the validation datasets. Finally, a radiomics–clinical score for prediction of positive LNs was 
obtained by applying a logistic regression multivariable model to the radiomics score and the clinical 
score, and the corresponding AUC was calculated for the clinical–radiomics model for both the 
training and the validation datasets. The AUC for the radiomics, the clinical and the clinical–
radiomics models were compared with the DeLong test [16]. 
Since the measurements of most radiomic features showed dependency according to the 
different CT reconstruction algorithms and were excluded from the previous analysis, we replicated 
all the above-mentioned analyses separately on the two groups of subjects, according to FBP and IR 
reconstruction algorithms including all the features that proved to be repeatable after test-retest 
analysis. A leave-one-out cross validation was performed for both algorithms and a LASSO logistic 
model was implemented with the same settings as previously described. For each subgroup of 
patients, AUC for the radiomics, clinical and clinical–radiomics models were compared with the 
DeLong test [16]. 
OS prediction: Overall survival was calculated from the date of CT to the date of death or last 
follow-up, whichever occurred first. We censored patients who had not died during the study period 
or until the date they were lost to follow-up, whichever occurred first, and we estimated their overall 
survival time. The LASSO Cox regression model was used to select the radiomic features that are 
most useful to predict OS. First a 10-fold cross-validation based on partial log-likelihood deviance 
was computed to find the best lambda parameter. The regularization strength was selected as the 
minimum value that minimizes the partial log-likelihood deviance. The R package “glmnet” was 
used to perform the LASSO Cox regression as previously described. We then combined the selected 
features into a radiomics score as a linear combination of the selected features weighted by their 
respective coefficients. The potential association of the radiomics score with OS was assessed in the 
training dataset and validated in the validation dataset by using Kaplan–Meier survival analysis. For 
this, the patients were classified into high-risk or low-risk groups according to the radiomics score, 
by using the third quartile as the threshold. The difference in the survival curves of the high-risk and 
low-risk groups was evaluated by using the Log–Rank test. The predictive accuracy of the radiomics 
score for OS was assessed in both datasets by calculating the Harrel concordance index (C-index) 
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with 95% Confidence Intervals (CI) [17]. The association of clinical variables (age, gender, side, site, 
nodule size, histological type, grading, pT and pN) with OS was assessed with univariable and 
multivariable Cox regression analysis. Multivariable analysis included the clinical variables with a p-
value < 0.10 at univariable analysis. A clinical score was then obtained as a linear combination of the 
selected clinical variables weighted by their respective coefficients and the corresponding C-index 
was calculated for the clinical model for both the training and the validation datasets. Finally, a 
radiomics–clinical score for prediction of OS was obtained by applying a Cox regression 
multivariable model to the radiomics score and clinical score, and the corresponding C-index was 
calculated for the clinical–radiomics model for both the training and the validation datasets. 
As described for positive LN prediction, we replicated all the above analyses separately on the 
two groups of subjects with the FBP and IR reconstruction algorithm. 
5. Conclusions 
In conclusion, a combined clinical–radiomics model was not superior to a single clinical or 
radiomics model in predicting LN metastases in lung cancer patients, whereas a radiomics score was 
able to significantly separate high-risk and low-risk patients for OS. 
For the prediction of OS, the combined clinical–radiomics model demonstrated the best model 
performance for CT reconstructed with IR. 
Based on these results, in the near future, clinical prediction of OS might include a radiomics 
score for better precision; furthermore, in similar radiomics studies, the extraction of radiomic 
features should include CT reconstructed with IR. 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6694/12/6/1432/s1, Figure 
S1: Number of radiomic features selected as the most reproducible, robust and reliable, Figure S2: ROC curves 
for prediction of positive lymph nodes in (a) the training set with FBP algorithm; (b) the validation set with FBP 
algorithm; (c) the training set with IR algorithm; (d) the validation set with IR algorithm according to clinical *, 
radiomics and clinical–radiomics models ^. (* clinical model includes site and nodule size as independent 
variables; ^ For the FBP algorithm: the clinical–radiomics model includes site, nodule size and radiomics score. 
For the IR algorithm: the clinical–radiomics model includes site and radiomics score. Nodule size was not 
included because of overlapping with the radiomic feature Shape_Max3DDiameter). 
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